Sign up
Pharma Capital

Faron Pharmaceuticals gains some early understanding of phase III trial data

The company is taking a closer look at the results from its INTEREST study
clinical trial written on a pad
Detailed analysis of the data and testing of product batches still needs to be conducted

Faron Pharmaceuticals Ltd (LON:FARN) said early follow-up analysis of its unsuccessful phase III clinical trial suggests the treatment did not produce the expected interferon-beta bioactivity seen in the phase I/II study.

The company said it is still too early to understand why this was the case, but it cited a number of possible causes. It is investigating the formulation of the drug, its administration and deactivation. 

READ: Faron Pharma assesses options after phase III disappointment

"Further detailed analysis of the data and testing of product batches still needs to be conducted, and therefore there is no guarantee that this will ultimately prove to be conclusive or, of the resultant implications of that analysis," Faron said in a short statement.

 

View full FARN profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.